RIA TAMALIA, - (2022) LUTESIUM-177 PROSTATE SPECIFIC MEMBRANE ANTIGEN (LUTESIUM-177-PSMA) SEBAGAI SEDIAAN TERAPEUTIK KANKER PROSTAT [KAJIAN PUSTAKA]. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A181034_Title.pdf Download (1MB) |
|
Text
S_PSSF_A181034_Chapter1.pdf Restricted to Repository staff only Download (325kB) |
|
Text
S_PSSF_A181034_Chapter2.pdf Restricted to Repository staff only Download (843kB) |
|
Text
S_PSSF_A181034_Chapter3.pdf Restricted to Repository staff only Download (584kB) |
|
Text
S_PSSF_A181034_Chapter4.pdf Restricted to Repository staff only Download (555kB) |
|
Text
S_PSSF_A181034_Chapter5.pdf Restricted to Repository staff only Download (196kB) |
|
Text
S_PSSF_A181034_Appendix.pdf Restricted to Repository staff only Download (285kB) |
Abstract
Pengobatan kanker prostat biasanya dilakukan dengan kemoterapi, operasi dan radiasi, namun pengobatan konvensional tersebut sering memberikan efek samping yang tidak ringan bagi pasien. Dalam beberapa tahun terakhir ini, telah dilaporkan bahwa radioligand Lutesium-177-PSMA berpotensi baik sebagai sediaan terapi kanker prostat. Kurangnya informasi bagi tenaga medis atas prospek positif penggunaan radiofarmaka Lutesium-177-PSMA mendorong penulis untuk menggali berbagai informasi yang terkait dengan efektivitas dan efek samping sediaan tersebut. Dalam telaah Pustaka ini digunakan metode PICOC dengan melakukan penelusuran dan mengevaluasi data primer ataupun data sekunder, baik dari jurnal nasional maupun internasional yang diterbitkan dalam kurun waktu 10 tahun terakhir. Hasil yang diperoleh menunjukkan bahwa pengobatan kanker prostat dengan radiofarmaka Lutesium-177-PSMA memberikan efek penurunan PSA (Prostate Specific Antigen) dan penurunan ALP (Alkaline Phosphatase) yang signifikan masing-masing berkisar ≥ 50% hingga lebih dari 90% dan 11-12% dengan efek samping minimal. Respon terapi dan besaran dosis berbanding lurus dengan tingkat keparahan dari kanker prostat yang diderita oleh pasien. Kajian yang diperoleh dari berbagai literatur ini diharapkan dapat digunakan sebagai saran rekomendasi, atau bahan pertimbangan bagi para tenaga medis dalam tata kelola terapi kanker prostat. --- Prostate cancer treatment is usually done with chemotherapy, surgery, and radiation, but these conventional treatments often have side effects that are not mild for the patient. In recent years, it has been reported that radioligand Lutetium-177- PSMA has good potential as an agent for prostate cancer therapy. The lack of information for medical personnel on the positive prospects for the use of the radiopharmaceutical Lutetium-177-PSMA prompted the authors to explore various information related to the effectiveness and side effects of these preparations. In this literature review, the PICOC method is used by searching and evaluating primary data or secondary data, both from national and international journals published in the last 10 years. The results obtained showed that the treatment of prostate cancer with radiopharmaceutical Lutetium-177-PSMA had a significant PSA (Prostate Specific Antigen) and ALP (Alkaline Phosphatase) reduction effect, respectively, ranging from ≥ 50% to more than 90% and 11-12% with minimal side effects. The response to therapy and the dose is directly proportional to the severity of prostate cancer suffered by the patient. The study obtained from various literature is expected to be used as a recommendation, or consideration for medical personnel in the management of prostate cancer therapy.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | kanker prostat, Lutetium-177-PSMA, PSA, ALP. --- prostate cancer, Lutetium-177-PSMA, PSA, ALP. |
| Subjects: | Q Science > Q Science (General) R Medicine > R Medicine (General) |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 14 Sep 2024 13:51 |
| Last Modified: | 14 Sep 2024 13:51 |
| URI: | http://repository.stfi.ac.id/id/eprint/1212 |
Actions (login required)
 |
View Item |
